Of note, in phase II and phase III trials on CGRP-mAbs, 46.3% of individuals with migraine were treatment naive or without a previous history of drug failure [7–10, 16, 17, 19, 20, 24, 26]. The gene discussed is CALCA; the disease is migraine disorder.